Avalon GloboCare to produce its first series of clinical-grade exosome products by end of 2019
Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr. David Jin tells Proactive Investors that the biotech company will be producing its first series of clinical grade exosome products, used for skincare and hair growth, by the second half of 2019.
Dr. Jin adds that the New Jersey-based company is collaborating with the Massachusetts Institute of Technology to develop an AI-enhanced protein design technology, which will allow the company to innovate in new cell therapy techniques.
Quick facts: Avalon GloboCare Corp
Market Cap: $191.41 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Avalon GloboCare Corp named herein, including the promotion by the Company of Avalon GloboCare Corp in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE